Company(ies): Merck & Co
Principal Therapy Area: Cancer
Dinaciclib is a pyrazolo[1,5-a]pyrimidine that potently and selectively inhibits cyclin-dependent kinases (CDKs) 1, 2, 5 and 9. Inhibition of CDK2/CDK1 in tumour cells leads to cell cycle arrest and apoptosis.
Dinaciclib was derived from a collaboration initiated in 1998 between Pharmacopeia and Schering-Plough. Pharmacopeia was acquired by Ligand Pharmaceuticals in December 2008, while Merck & Co and Schering-Plough completed their merger in November 2009, with the surviving company renamed as Merck & Co.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focusing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org